Orforglipron FAQ: common questions answered
A daily GLP-1 pill approved in the US for adult weight management.
Also called: LY3502970, LY-3502970, OWL833, Foundayo.
Oral GLP-1 agonists · Nonpeptide GLP-1 receptor agonist · Evidence: Approved drug.
- Is Orforglipron FDA-approved? Yes: Foundayo (long-term weight management with diet and activity in adults with obesity, or overweight plus a weight-related condition.). Approved April 1, 2026. US diabetes indication not identified. Approval does not authorize research products or unrestricted compounded copies.
- How do people take it? By mouth, once daily. Long-term weight management. Source: drug label.
- What's the difference between Orforglipron and Tirzepatide? Orforglipron: a daily GLP-1 pill approved in the US for adult weight management. Tirzepatide: a weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects. Why people pair them: an isolated online report combines both for weight loss.
- Can I take it with Tirzepatide? An isolated online report combines both for weight loss. No controlled human evidence for concurrent use was found. Both activate GLP-1; the label advises against another GLP-1 agonist. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? No, it is not on the banned list (WADA 2026). USADA lists Foundayo among currently permitted GLP-1 medicines. WADA’s 2026 monitoring list names semaglutide and tirzepatide, not orforglipron.
- How do I store it once opened? No mixing or injectable preparation is specified for approved tablets.
Related to Orforglipron
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- FDA Approves First New Molecular Entity Under National Priority Voucher Program, FDA · 2026
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, FDA · 2026
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, FDA · FDA · 2026
- Foundayo, European Medicines Agency · 2026
- Foundayo (orforglipron) tablets, FDA · 2026
- FOUNDAYO- orforglipron tablet, film coated, DailyMed · DailyMed · 2026
- The 2026 Monitoring Program, World Anti-Doping Agency · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- UK first in Europe to authorise orforglipron for weight management and type 2 diabetes, MHRA · 2026
- Weight Loss Drugs: What athletes need to know about GLP-1s, USADA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, FDA · FDA · 2000
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.